Volume Spike Investor

King Pharmaceuticals Inc. (NYSE: KG) stock fell more than 2 percent to $9.12 in after hours trading as one of the more active issues. The company said an FDA panel is requiring more study of its heart-imaging candidate Corvue. The FDA said King failed to show Corvue worked as well as the approved drug adenosine heart disease diagnosis tests. — Mike Tarsala